XML 30 R20.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Note 13 - Segment Information | 9 Months Ended
--- | ---
Oct. 01, 2022
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | 13. Segment Information The Company follows ASC 280, “Segment Reporting,” which establishes standards for companies to report information about operating segments, geographic areas and major customers. The accounting policies of each reportable segment are the same as those described in the summary of significant accounting policies (see Note 1 to the Company’s Consolidated Financial Statements included in its Annual Report on Form 10-K for the year ended January 1, 2022). Segment operating income (loss) includes selling, general and administrative expenses directly attributable to that segment as well as charges for allocating corporate costs to each of the operating segments. The following tables reflect the results of the reportable segments consistent with the Company’s management system:
Thirteen Weeks Ended October 1, 2022 |  | Engineering |  |  | Specialty Health Care |  |  | Information Technology |  |  | Corporate |  |  | Total |
Revenue |  | $ | 20,922 |  |  | $ | 27,997 |  |  | $ | 9,233 |  |  | $ | - |  |  | $ | 58,152 |
Cost of services |  |  | 15,594 |  |  |  | 19,014 |  |  |  | 6,186 |  |  |  | - |  |  |  | 40,794 |
Gross profit |  |  | 5,328 |  |  |  | 8,983 |  |  |  | 3,047 |  |  |  | - |  |  |  | 17,358 |
Selling, general and administrative |  |  | 4,531 |  |  |  | 5,933 |  |  |  | 2,087 |  |  |  | - |  |  |  | 12,551 |
Depreciation and amortization of property and equipment |  |  | 136 |  |  |  | 101 |  |  |  | 29 |  |  |  | - |  |  |  | 266 |
Gain on sale of assets |  |  | (219 | ) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (219 | )
Operating income |  | $ | 880 |  |  | $ | 2,949 |  |  | $ | 931 |  |  | $ | - |  |  |  | 4,760 |
Total assets as of October 1, 2022 |  | $ | 32,343 |  |  | $ | 33,280 |  |  | $ | 8,579 |  |  | $ | 2,607 |  |  | $ | 76,809 |
Capital expenditures |  | $ | 207 |  |  | $ | 9 |  |  | $ | 39 |  |  | $ | 266 |  |  | $ | 521 |
Thirteen Weeks Ended October 2, 2021 |  | Engineering |  |  | Specialty Health Care |  |  | Information Technology |  |  | Corporate |  |  | Total |
Revenue |  | $ | 16,482 |  |  | $ | 19,646 |  |  | $ | 9,343 |  |  | $ | - |  |  | $ | 45,471 |
Cost of services |  |  | 12,694 |  |  |  | 14,115 |  |  |  | 6,448 |  |  |  | - |  |  |  | 33,257 |
Gross profit |  |  | 3,788 |  |  |  | 5,531 |  |  |  | 2,895 |  |  |  | - |  |  |  | 12,214 |
Selling, general and administrative |  |  | 3,834 |  |  |  | 4,415 |  |  |  | 2,133 |  |  |  | - |  |  |  | 10,382 |
Depreciation and amortization of property and equipment |  |  | 120 |  |  |  | 99 |  |  |  | 31 |  |  |  | - |  |  |  | 250 |
Amortization of acquired intangible assets |  |  | 6 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 6 |
Gain on sale of assets |  |  | (2,151 | ) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (2,151 | )
Operating income |  | $ | 1,979 |  |  | $ | 1,017 |  |  | $ | 731 |  |  | $ | - |  |  | $ | 3,727 |
Total assets as of October 2, 2021 |  | $ | 29,020 |  |  | $ | 26,483 |  |  | $ | 8,560 |  |  | $ | 6,228 |  |  | $ | 70,291 |
Capital expenditures |  | $ | 16 |  |  | $ | 168 |  |  | $ | 35 |  |  | $ | 139 |  |  | $ | 358 |
Thirty-Nine Weeks Ended October 1, 2022 |  | Engineering |  |  | Specialty Health Care |  |  | Information Technology |  |  | Corporate |  |  | Total |
Revenue |  | $ | 61,726 |  |  | $ | 123,638 |  |  | $ | 29,095 |  |  | $ | - |  |  | $ | 214,459 |
Cost of services |  |  | 45,653 |  |  |  | 86,772 |  |  |  | 19,573 |  |  |  | - |  |  |  | 151,998 |
Gross profit |  |  | 16,073 |  |  |  | 36,866 |  |  |  | 9,522 |  |  |  | - |  |  |  | 62,461 |
Selling, general and administrative |  |  | 12,659 |  |  |  | 21,203 |  |  |  | 6,100 |  |  |  | - |  |  |  | 39,962 |
Depreciation and amortization of property and equipment |  |  | 332 |  |  |  | 322 |  |  |  | 75 |  |  |  | - |  |  |  | 729 |
Gain on sale of assets |  |  | (219 | ) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (219 | )
Operating income |  | $ | 3,301 |  |  | $ | 15,341 |  |  | $ | 3,347 |  |  | $ | - |  |  | $ | 21,989 |
Total assets as of October 1, 2022 |  | $ | 32,343 |  |  | $ | 33,280 |  |  | $ | 8,579 |  |  | $ | 2,607 |  |  | $ | 76,809 |
Capital expenditures |  | $ | 496 |  |  | $ | 57 |  |  | $ | 102 |  |  | $ | 275 |  |  | $ | 930 |
Thirty-Nine Weeks Ended October 2, 2021 |  | Engineering |  |  | Specialty Health Care |  |  | Information Technology |  |  | Corporate |  |  | Total |
Revenue |  | $ | 47,882 |  |  | $ | 63,723 |  |  | $ | 27,348 |  |  | $ | - |  |  | $ | 138,953 |
Cost of services |  |  | 36,875 |  |  |  | 47,564 |  |  |  | 19,184 |  |  |  | - |  |  |  | 103,623 |
Gross profit |  |  | 11,007 |  |  |  | 16,159 |  |  |  | 8,164 |  |  |  | - |  |  |  | 35,330 |
Selling, general and administrative |  |  | 10,570 |  |  |  | 12,937 |  |  |  | 6,059 |  |  |  | - |  |  |  | 29,566 |
Depreciation and amortization of property and equipment |  |  | 428 |  |  |  | 260 |  |  |  | 87 |  |  |  | - |  |  |  | 775 |
Amortization of acquired intangible assets |  |  | 95 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 95 |
Gain on sale of assets |  |  | (2,151 | ) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (2,151 | )
Operating income |  | $ | 2,065 |  |  | $ | 2,962 |  |  | $ | 2,018 |  |  | $ | - |  |  | $ | 7,045 |
Total assets as of October 2, 2021 |  | $ | 29,020 |  |  | $ | 26,483 |  |  | $ | 8,560 |  |  | $ | 6,228 |  |  | $ | 70,291 |
Capital expenditures |  | $ | 55 |  |  | $ | 235 |  |  | $ | 44 |  |  | $ | 165 |  |  | $ | 499 |
The Company derives a majority of its revenue from offices in the United States. Revenues reported for each operating segment are all from external customers. The Company is domiciled in the United States and its segments operate in the United States, Canada, Puerto Rico and Serbia. Revenue by geographic area for the thirteen and thirty-nine weeks ended October 1, 2022 and October 2, 2021 was as follows:
|  | Thirteen Weeks Ended |  |  | Thirty-Nine Weeks Ended |
|  | October 1, 2022 |  |  | October 2, 2021 |  |  | October 1, 2022 |  |  | October 2, 2021 |
Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U. S. |  | $ | 55,180 |  |  | $ | 41,584 |  |  | $ | 205,162 |  |  | $ | 124,337 |
Canada |  |  | 1,091 |  |  |  | 1,912 |  |  |  | 3,555 |  |  |  | 8,371 |
Puerto Rico |  |  | 1,261 |  |  |  | 1,245 |  |  |  | 3,760 |  |  |  | 4,128 |
Serbia |  |  | 620 |  |  |  | 730 |  |  |  | 1,982 |  |  |  | 2,117 |
|  | $ | 58,152 |  |  | $ | 45,471 |  |  | $ | 214,459 |  |  | $ | 138,953 |
Total assets by geographic area as of the reported periods were as follows:
|  | October 1, 2022 |  |  | January 1, 2022 |
Total assets |  |  |  |  |  |  |  |
U. S. |  | $ | 73,700 |  |  | $ | 69,566 |
Canada |  |  | 959 |  |  |  | 1,327 |
Puerto Rico |  |  | 1,351 |  |  |  | 963 |
Serbia |  |  | 799 |  |  |  | 996 |
|  | $ | 76,809 |  |  | $ | 72,852 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration